Extrait

This is an open, randomized, multicenter clinical trial. Objectives: - To describe the safety profiles during the 21 days following each primary and booster injection. - To describe the immune response 21 days after each primary and booster injection of each formulation. - To describe the antibody persistence after the first vaccination

Critère d'inclusion

• Influenza ,Orthomyxoviridae Infections ,Influenza A Virus Infection

Liens

• ictrp
• nct